β-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: Part 2. Optimization of α-amino substituents
Authors:
- Shyh-Ming YangSYShyh-Ming Yang
- Robert H. ScannevinRSRobert H. Scannevin
- Bingbing WangBWBingbing Wang
- Sharon L. BurkeSBSharon L. Burke
- Zhihong HuangZHZhihong Huang
- Prabha KarnachiPKPrabha Karnachi
- Lawrence J. WilsonLWLawrence J. Wilson
- Kenneth J. RhodesKRKenneth J. Rhodes
- Bharat LaguBLBharat Lagu
- William V. MurrayWMWilliam V. Murray
- 1 February 2008
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (3) , 1140-1145
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Matrix Metalloproteinases as Valid Clinical TargetCurrent Pharmaceutical Design, 2007
- Matrix Metalloproteinases as Therapeutic Targets in CancerCurrent Cancer Drug Targets, 2005
- Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospectsExpert Opinion on Therapeutic Targets, 2003
- Effects of Matrix Metalloproteinase-9 Gene Knock-Out on the Proteolysis of Blood–Brain Barrier and White Matter Components after Cerebral IschemiaThe Journal of Neuroscience, 2001
- Matrix Metalloproteinase Expression After Human Cardioembolic StrokeStroke, 2001
- Metalloproteinases in biology and pathology of the nervous systemNature Reviews Neuroscience, 2001
- Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosisExpert Opinion on Investigational Drugs, 2000
- The potential use of MMP inhibitors to treat CNS diseasesExpert Opinion on Investigational Drugs, 1999
- Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in RatsStroke, 1998
- Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemiaNeuroscience Letters, 1997